Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name	Generic Name	Therapeutic Area	Recommendation Type	Project Status	Date Submission Received Sort ascending	Date Recommendation Issued
Cayston	Aztreonam for inhalation solution	Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections	List with clinical criteria and/or conditions	Complete	Dec 2, 2010	Jul 18, 2011
Daxas	Roflumilast	Chronic obstructive pulmonary disease	Do not list	Complete	Nov 30, 2010	Jul 27, 2011
Targin	Oxycodone / naloxone	Pain, Moderate to severe and relief of opioid-induced constipation		Cancelled	Nov 30, 2010
Victoza	Liraglutide	Diabetes mellitus, Type 2	Do not list	Complete	Nov 29, 2010	Sep 28, 2011
Pradaxa	Dabigatran etexilate	Atrial fibrillation prevention of stroke and systemic embolism	List with clinical criteria and/or conditions	Complete	Oct 28, 2010	Jun 22, 2011
VPRIV	Velaglucerase alfa	Gaucher Disease	List with clinical criteria and/or conditions	Complete	Oct 28, 2010	Apr 25, 2011
Uloric	Febuxostat	Gout	List with clinical criteria and/or conditions	Complete	Oct 27, 2010	Apr 25, 2011
Vimpat	Lacosamide	Epilepsy, partial onset seizures	List with clinical criteria and/or conditions	Complete	Oct 25, 2010	Apr 25, 2011
BuTrans	Buprenorphine transdermal patch	Pain, persistent (moderate intensity)		Cancelled	Oct 15, 2010
Finacea	Azelaic acid	Rosacea	List	Complete	Aug 31, 2010	Feb 16, 2011

Last Updated : May 12, 2024